Loading page…

Report overview

The report records consolidated net sales of ¥386,709 million for FY ended March 2016, down 4.3% year on year amid weak demand in core markets. It identifies life sciences as a third business pillar and reports that JSR Life Sciences was established as a global business unit in April 2016. It also describes a joint JSR-Keio medical and chemical innovation center, then expected to begin operations in October 2017.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2015-2016
Period: 1 April 2015 – 31 March 2016
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

No ESG data is available for this report.

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services